Women taking the 'blue pill' (sildenafil citrate): such a big deal?
| Autor: | LO MONTE, Giuseppe, Graziano, Angela, Piva, Isabella, Marci, Roberto |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Sulfonamides
sildenafil citrate Phosphodiesterase 5 Inhibitors Piperazines NO Diagnostic and Statistical Manual of Mental Disorders Purines Female sexual arousal disorder (FSAD) Phosphodiesterase type 5 inhibitors Sildenafil citrate phosphodiesterase type 5 inhibitors Commentary female sexual arousal disorder (FSAD) Humans Female Sexual Dysfunctions Psychological |
| Zdroj: | Drug Design, Development and Therapy |
| ISSN: | 1177-8881 |
| Popis: | For years, phosphodiesterase type 5 inhibitors have been used for the treatment of erectile dysfunctions. Due to the similarities between male and female sexual response, several studies have assessed the effects of sildenafil citrate (Viagra(®)) in women affected by female sexual arousal disorder. The results are still conflicting and the drug is not devoid of adverse effects. Furthermore, female sexual arousal disorder is a heterogeneous condition whose underlying causes are difficult to diagnose and appropriate treatment requires a thorough sexual, psychological, and medical history along with specialist consultations. The clinician should pursue a global approach to the patient with sexual difficulties, while non-hormonal treatment such as phosphodiesterase type 5 inhibitors (ie, sildenafil citrate) should be kept as the last option. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|